Some current areas of research


Rhabdomyosarcoma is a type of soft tissue sarcoma – a cancer that starts in muscles. It can occur in children or adults, though it’s usually in children and adolescents.

Better classification of tumours, special tests to classify tumours and predict how they will respond to different treatments, enabling potentially more effective personalised treatment

Kinder treatments such as alternative methods of delivering radiation therapy which limit impact on healthy body tissue

New drugs to target specific parts of cancer cells, some of which are already used for some adult cancers 

Immunotherapy, developing new drugs which cause the body’s immune system to attack certain parts of the cancer cell such as the PAX-FOX01 protein which is common to many ARMS cells.

Find out more about current themes in RMS research.

Some Key Researchers and Samples of Research Papers

Research is ongoing at many institutes, hospitals and centres around the world. Some key people worth following are:

Charles Keller, Scientific Director, Children’s Cancer - Therapy Development Institute, Portland, Oregon  http://www.cc-tdi.org/mission

Professor Janet Shipley, Head of the Division of Molecular Pathology, Institute of Cancer Research, London 
https://www.icr.ac.uk/our-research/research-divisions/division-of-molecular-pathology


The links below are to a random selection of research papers which may also be of interest:

Pediatric Rhabdomyosarcoma, recent genetic and molecular characterisation  (2015)
https://www.ncbi.nlm.nih.gov/pubmed/26349418

Childhood Rhabdomyosarcoma Treatment (PDQ®)  31/8/2017)
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032852/

Consensus and controversies regarding the treatment of rhabdomyosarcoma  (14/9/2017)
https://www.ncbi.nlm.nih.gov/pubmed/28905489?dopt=Abstract

Familial Investigations of Childhood Cancer Predisposition (SJFAMILY)  (28/8/2017)
https://clinicaltrials.gov/ct2/show/NCT03050268?term=rhabdomyosarcoma&recrs=abc&lup_s=07%2F31%2F2017&lup_d=30

PET/CT versus bone marrow biopsy in the initial evaluation of bone marrow infiltration in various pediatric malignancies  (13/9/2017)
https://www.ncbi.nlm.nih.gov/pubmed/28901637?dopt=Abstract

A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo  (11/9/2017)
https://www.ncbi.nlm.nih.gov/pubmed/28892044?dopt=Abstract

Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands  (7/9/2017)
https://www.ncbi.nlm.nih.gov/pubmed/28881358?dopt=Abstract

Successful treatment of metastatic alveolar rhabdomyosarcoma with MGMT gene promoter methylation by temozolomide-based combination chemotherapy.  (17/8/2017)
https://www.ncbi.nlm.nih.gov/pubmed/28834127?dopt=Abstract


Rhabdomyosarcoma (RMS)

RMS is a rare and aggressive form of soft tissue cancer.  RMS has particularly high incidence amongst infant and adolescent cancer patients.  There is evidence to suggest that sarcomas have a disproportionately high genetic basis, unlike cancers that are clearly very largely due to environmental factors, like lung cancer and skin cancers.

Disclaimer

‘1000 faces of RMS’ is a patient and research resource only and we offer no medical expertise or advice. Nor are we qualified to carry out any validation of the web sites that we link to.

Our social media